Sep 25, 2018 Checkpoint Therapeutics Announces Presentation of Updated Data from Phase 1/2 Trial of EGFR Inhibitor CK-101
Sep 06, 2018 Checkpoint Therapeutics Announces Encouraging Safety and Efficacy Data from Phase 1/2 Clinical Trial of EGFR Inhibitor CK-101
Aug 30, 2018 Checkpoint Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
Aug 13, 2018 Checkpoint Therapeutics Announces Clinical Data on EGFR Inhibitor CK-101 Selected for Late-Breaking Oral Presentation at IASLC 19th World Conference on Lung Cancer
Aug 07, 2018 Checkpoint Therapeutics Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights
May 10, 2018 Checkpoint Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights
Apr 18, 2018 Checkpoint Therapeutics Reports Preclinical Data on BET Inhibitor CK-103 at the American Association for Cancer Research Annual Meeting
Mar 21, 2018 Checkpoint Therapeutics Initiates Dose Expansion Portion of Phase 1 Trial of Anti-PD-L1 Antibody CK-301